ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $558,103,004 | -12.5% | 20,563,854 | -0.9% | 0.02% | -11.1% |
Q2 2023 | $637,594,299 | -10.8% | 20,741,519 | +4.5% | 0.02% | -14.3% |
Q1 2023 | $715,153,783 | -6.8% | 19,848,842 | +2.2% | 0.02% | -12.5% |
Q4 2022 | $767,211,684 | +4.5% | 19,413,251 | +6.3% | 0.02% | -4.0% |
Q3 2022 | $734,092,000 | -5.1% | 18,270,089 | -0.7% | 0.02% | 0.0% |
Q2 2022 | $773,439,000 | +13.5% | 18,397,640 | +5.2% | 0.02% | +38.9% |
Q1 2022 | $681,145,000 | +2.3% | 17,483,188 | +4.6% | 0.02% | +5.9% |
Q4 2021 | $666,107,000 | +19.2% | 16,715,324 | +8.1% | 0.02% | +6.2% |
Q3 2021 | $558,754,000 | +32.5% | 15,460,845 | +50.3% | 0.02% | +33.3% |
Q2 2021 | $421,691,000 | -29.3% | 10,287,641 | -24.7% | 0.01% | -33.3% |
Q1 2021 | $596,048,000 | +31.5% | 13,664,581 | +50.9% | 0.02% | +28.6% |
Q4 2020 | $453,128,000 | +188.6% | 9,053,545 | +142.6% | 0.01% | +133.3% |
Q3 2020 | $156,989,000 | +57.7% | 3,731,632 | +82.0% | 0.01% | +50.0% |
Q2 2020 | $99,534,000 | – | 2,050,145 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |